Preliminary results from the Oxford Stone Group

RNS Number : 8097M

Feedback PLC

11 May 2015

 

11 May 2015

Feedback plc

("Feedback" or the "Company")

Preliminary results from the Oxford Stone Group using TexRAD research software in the analysis of kidney stones

Feedback plc (AIM: FDBK), the medical imaging software company, previously announced on 13 April 2015 that it had signed a research agreement with the Oxford Stone Group at the University of Oxford & Oxford University Hospital NHS Trust ("Oxford"), UK to investigate the potential future clinical application of Feedback's TexRAD texture analysis software on computed tomography (CT) image data of patients with kidney stones.

The preliminary results from a 38 patient retrospective study so far are promising. Researchers at Oxford have demonstrated that TexRAD texture analysis could identify from pre-treatment CT scans which patients would have "successful" shockwave lithotripsy (SWL) therapy from those who would have "unsuccessful" therapy.

The research was led by Mr Ben Turney (Bernard Senior Clinical Researcher in Urology at the University of Oxford and Honorary Consultant Urological Surgeon) and carried out by Mr Daniel Stevens (Academic Clinical fellow in Urology at the University of Oxford).

Mr Ben Turney, a leading authority on stone disease in the UK, commented:  

"Shock Wave Lithotripsy (SWL) is a well-established non-invasive surgical procedure for urolithiasis. However around 30-40% of patients do not achieve stone clearance and proceed to alternative treatments. We have demonstrated in this first preliminary study that TexRAD CT textural analysis appears to be an independent novel predictive biomarker for SWL success. TexRAD CT texture analysis may be a useful tool for risk-stratification and more accurately triaging those patients who will benefit from SWL. The next step is to undertake a prospective study to ascertain the clinical utility of this finding in a large population. Additionally, we shall explore other research questions such as assessing the stone composition and differentiate between actual stones and those conditions that mimic stone-like characteristics to increase diagnostic confidence and prevent unnecessary costly investigation and treatments." 

Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company's subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented:

"We are delighted with the positive results from the preliminary study within a few weeks of signing the research agreement with Mr Ben Turney and the team at Oxford. This is very encouraging news and provides an opportunity for Feedback Plc to develop a TexRAD based kidney stone software product dedicated to the management of kidney stone patients."

Mr Ben Turney and team have further submitted their preliminary results as an abstract for a possible presentation to the Challenges in Endourology meeting (http://www.challenges-endourology.com) in Paris in June 2015.    

For further information contact:

Feedback plc	Tel: [phone]
Simon Barrell / Trevor Brown / Tom Charlton
Sanlam Securities UK (Nominated Adviser and Joint Broker)	Tel: [phone]
Simon Clements / Virginia Bull
Peterhouse Corporate Finance Ltd (Joint Broker)	Tel: [phone]
Lucy Williams / Duncan Vasey

Notes to editors:

TexRAD is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans. This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than is readily visible to the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging-Biomarker') in confident decision-making: it has the potential to assess the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer. Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'. TexRAD is manufactured under licence by company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.

 

END

 

 

MSCEALSFFEXSEFF